Negative Pressure Wound Therapy for the Treatment of Chronic Pressure Wounds
NCT ID: NCT00691821
Last Updated: 2011-07-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
184 participants
INTERVENTIONAL
2009-04-30
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Comparing V.A.C. Negative Pressure Wound Therapy (NPWT) to Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Amputation Wounds
NCT00837096
NPWTi on Closure of Chronic Pressure Sores
NCT05598398
Negative Pressure Wound Therapy. Therapy Effects and the Impact on the Patient's Quality of Life
NCT01191567
Efficacy of Quantum NPWT With Simultaneous Irrigation on Reduction of Wound Volume in Stage III/IV Pressure Ulcers.
NCT01734109
Randomized, Controlled Multicenter Trial of Vacuum Assisted Closure Therapy™ in Diabetic Foot Ulcers
NCT00432965
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a prospective, randomized, open-label, controlled clinical trial comparing standardized wound dressing (control arm) to NPWT (experimental arm) for the treatment of chronic pressure wounds of the pelvic region. NPWT will be performed using the Vacuum-Assisted Closure System (V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario). NPWT will be compared to the present recommended state of the art wound dressings in subjects who would be candidates for either type of wound therapy. Both arms will receive standard wound care (e.g., debridement, preventative care, infection control, etc.). The efficacy, effectiveness, safety, and quality of life will be evaluated for standardized wound dressing versus NPWT. Complications associated with either form of wound care will be documented. An economic evaluation will be conducted in order to assess the cost-effectiveness and cost-utility of NPWT compared to standard wound dressing. It is anticipated that 184 subjects will be enrolled and randomized over a 1.5 year period. All subjects providing consent and meeting inclusion/exclusion criteria will be randomized to either treatment arm and followed for 12 weeks. Patients who have wound closure within the 12-week study period will continue to have wound care visits as scheduled. All subjects will have Wound Evaluation Visits and Wound Dressing Change Visits. Wound Evaluation Visits will occur at baseline, 2, 4, 6, 8 and 12 weeks after the date of randomization, where following removal of the dressing, a detailed wound assessment (e.g., wound characteristics, measurements) will be done and healthcare resource utilization will be collected. Disease specific quality of life measures and preference based quality of life measures (EQ-5D) will be collected at baseline, 6 weeks and at 12 weeks. Dressing Change Visits will occur as clinically required and the frequency of dressing changes per week will be allowed to vary over the 12 weeks of the study. During the dressing change visits, subjects will be monitored for wound infection and other complications. Subjects may be enrolled and randomized in the clinic and transferred to the community with continued follow-up completed by the appropriate Community Care Access Centre.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Standard Dressings
Standard Dressings
Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).
2
Negative Pressure Wound Therapy
Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])
Participants will receive negative pressure wound therapy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard Dressings
Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).
Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])
Participants will receive negative pressure wound therapy.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. All chronic pressure wounds of the pelvic region except trochanteric wounds.
3. Chronic pressure wound defined as the presence of a pressure wound for \> 6 weeks and \< 6 months with no sign of improvement in healing
4. Wound size surface area \> 2cm2
5. Stage III-IV pressure ulcer according to the National Pressure Ulcer Advisory Panel (NPUAP)
6. No clinical signs of active infection at the wound site and currently not on antibiotics
7. Willingness to off-load or pressure redistribute ulcer
Exclusion Criteria
2. A wound with necrotic tissue unable to tolerate debridement
3. Exposed blood vessels and/or organs within the wound
4. Chronic osteomyelitis (as determined by biopsy) or osteomyelitis that is not treatable by debridement and antibiotics
5. Non-enteric or unexplored fistulae
6. Wounds requiring hemostasis (i.e., that the flow of blood be stopped) for local bleeding
7. Alternate etiology for non-healing
8. Concomitant conditions that in the judgment of the investigator would make the subject inappropriate for entry to the study (e.g., malignancy in wound, malignancy less than 1-year disease free interval, previous or current irradiation, known immunodeficiency and/or major uncorrected medical disorders such as serious non-malignant disease, serious cardiovascular or pulmonary disease, lupus, inflammatory bowel disease, palliative care or sickle cell disease)
9. Poor nutritional status as determined by a Braden Scale Nutritional Assessment score of 2 or 1 with a serum albumin \< 25 g/L and hemoglobin \< 90 g/L
10. Currently taking medication that may interfere with wound healing (e.g., oral systemic steroids, immunosuppressive drugs, unfractionated heparin infusion)
11. Women who are currently pregnant or are breast feeding; or women of child bearing potential who are not currently taking adequate birth control
12. Participation in another investigative drug or device trial currently or within the last 30 days
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ontario Ministry of Health and Long Term Care
OTHER_GOV
Unity Health Toronto
OTHER
Women's College Hospital
OTHER
Hamilton Niagara Haldimand Brant Community Care Access Centre
OTHER
Toronto Central Community Care Access Centre
OTHER
St. Joseph's Healthcare Hamilton
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Programs for Assessment of Technology in Health (PATH) Research Institute
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ron Goeree, MA
Role: STUDY_CHAIR
Programs for Assessment of Technology in Health Research Institute
James Mahoney, MD
Role: PRINCIPAL_INVESTIGATOR
Unity Health Toronto
Gary Sibbald, MD
Role: PRINCIPAL_INVESTIGATOR
Women's College
Maureen Kitson
Role: PRINCIPAL_INVESTIGATOR
Niagara Region Community Care Access Centre
Joanne Greco, BScN
Role: PRINCIPAL_INVESTIGATOR
Toronto Central Community Care Access Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Niagara Branch - Hamilton Niagara Haldimand Brant Community Care Access Centre
Saint Catherines, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Women's College Hospital
Toronto, Ontario, Canada
Toronto Central Community Care Access Centre
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HTA012-0801-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.